Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone
Recruiting · NCT06321679 · Observational (researchers observe without assigning treatment) · Lead sponsor: European Institute of Oncology
View the official record on ClinicalTrials.gov →Interventions studied
Imaging evaluation
What this trial is about
This study is aimed to compare whole body MRI (WB-MRI) with Bone Scintigraphy (BS) and Computerized Tomography (CT) scans in patients receiving treatment for metastatic castration-resistant prostate cancer to the bone. This is a monocentric, prospective observational study.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Histological diagnosis of castration-resistant prostate cancer,
- Single or multiple bone metastases,
- Life expectancy of over 6 months,
- No current active malignancy other than prostate cancer,
- Provision of written informed consent.
Exclusion criteria
- Absolute contraindication to WB-MRI, CT or BS,
- Radical treatment of sole site of metastatic disease (e.g. Cyberknife to solitary metastatic lesion),
- Psychological, familial, sociological or geographical conditions that would hamper compliance with the study protocol; such conditions are to be discussed with the patient as part of the informed consent process.
Where it is running
1 location listed.
- IEO Istituto Europeo di Oncologia - Milan, Italy